Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular Phase I/II, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AZD4512 Monotherapy or in Combination With Anticancer Agent(s) in Participants With Acute Lymphoblastic Leukemia

NCT07109219 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07109219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07109219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular Phase I/II, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AZD4512 Monotherapy or in Combination With Anticancer Agent(s) in Participants With Acute Lymphoblastic Leukemia
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 12, 2025
Completion date
July 3, 2028
Enrollment
83 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia (b-all)